|
- Altimmune a clinical stage biopharmaceutical company
Altimmune a clinical stage biopharmaceutical company developing peptide-based therapeutics Our focus is developing next generation peptide therapeutics for obesity and liver disease
- Altimmune – Investors Overview
The Investor Relations website contains information about Altimmune's business for stockholders, potential investors, and financial analysts
- Press Releases – Altimmune
GAITHERSBURG, Md , Nov 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and
- Our Pipeline - Altimmune
910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450 ALTIMMUNE About Us Pipeline Clinical Trials Partnerships Careers Contact Us Expanded Access Policy Terms Conditions Privacy Policy PIPELINE Our Pipeline Pemvidutide
- ABOUT US | Altimmune Website
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases
- In The News – Altimmune
Source FirstWord Pharma Go to article Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart March 27, 2024 Source CNBC
- Altimmune Announces Successful Completion of End-of-Phase 2 Meeting . . .
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics The Company is developing pemvidutide, a GLP-1 glucagon dual receptor agonist for the treatment of obesity and MASH
- Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide . . .
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics The Company is developing pemvidutide, a GLP-1 glucagon dual receptor agonist for the treatment of obesity and MASH
|
|
|